TrialHepatology communications2024

Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction-associated steatohepatitis.

Sven M Francque et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.